A drug typically takes around 10 to 15 years to undergo clinical trials, and after completing them, it reaches the final step of approval. There are more big tests on the way in the market spectrum. This might present an opportunity for small biotech to marketize their drugs on their own, which will lead them to collaborate with a large company in the drug development process. For decades, the underdeveloped players would try to crack a commercial deal with large companies to expand their sales network. The overall investigation has found that the times have changed for the biotech companies.
The company's valuable attempt to introduce scientific advancements like genomics and precision medicine has established elevated advanced disease niches. This allowed small companies to walk step-by-step with the largest key players in the global market. Starting to commercialize biotech products on their own requires a distinct market that is competitive and more accountable in all aspects and processes, similar to regulatory trials. The biopharma has witnessed the change and impact on the vast market for a few years, especially from the four competitive players.
Verona Pharma’s ohtuvayre was a discovery of a new inhaled therapy that started a new mechanism against the disease. Verona stood strong in COPD with this newly discovered drug against Sanofi, GSK, and Regeneron. Verona remarkably marketized ohtuvayre that interests huge pharma companies to invest in them.
Madrigal Therapeutics revolutionized the global biopharma industry last year in March by receiving FDA approval for its first-ever MASH with its oral THR-beta agonist Rezdiffra. Madrigal also commercialized their drug on their own and has also predicted Rezdiffra to hit milestones in the coming years. The confidence is indirectly driving the global market.
Pfizer, for five years, ruled the market with its approval for Vyndamax and Vyndaqel in 2019. Pfizer remained unbeatable due to its remarkable tafamidis portfolio with $5.4 billion in sales on the tafamidis line in 2024. BridgeBio challenged Pfizer in all possible ways, which attracted investors to BridgeBio’s performance.
Insmed, a New Jersey biotech firm, is walking on the path of Madrigal, BridgeBio, and Verona. Insmed is currently working on the candidate brensocatib for bronchiectasis. It will be used for oral consumption, and brensocatib holds various advantages. Insmed is awaiting approval from the FDA to be officially declared as the first therapy for bronchiectasis.
